Exosomal delivery of lncRNA RPL23AP82 promotes gemcitabine resistance in pancreatic ductal adenocarcinoma

SUN Yunpeng; WU Huanhuan; ZHUANG Lei; CHEN Haoran; XU Bo; HUANG Xiaming

doi:10.14188/j.1671-8852.2023.0508

您当前的位置：

首页 >

文章列表页 >

Exosomal delivery of lncRNA RPL23AP82 promotes gemcitabine resistance in pancreatic ductal adenocarcinoma

更新时间：2026-11-05

- Exosomal delivery of lncRNA RPL23AP82 promotes gemcitabine resistance in pancreatic ductal adenocarcinoma
- Medical Journal of Wuhan University Vol. 46, Issue 7, Pages: 850-856(2025)
- 作者机构：
  
  1.温州医科大学附属第一医院，肝胆胰外科，浙江温州 325000
  2.温州医科大学附属第一医院，麻醉复苏室，浙江温州 325000
  3.温州医科大学第一临床学院新医科班浙江温州 325000
- 作者简介：
- 基金信息：
- DOI：10.14188/j.1671-8852.2023.0508
  CLC： R735.9
- Received：18 September 2023，
  
  Published：25 July 2025
- 稿件说明：
移动端阅览
孙运鹏,吴欢欢,庄磊等.外泌体传递lncRNA RPL23AP82促进胰腺导管腺癌吉西他滨耐药[J].武汉大学学报（医学版）,2025,46(07):850-856.

SUN Yunpeng,WU Huanhuan,ZHUANG Lei,et al.Exosomal delivery of lncRNA RPL23AP82 promotes gemcitabine resistance in pancreatic ductal adenocarcinoma[J].Medical Journal of Wuhan University,2025,46(07):850-856.
孙运鹏,吴欢欢,庄磊等.外泌体传递lncRNA RPL23AP82促进胰腺导管腺癌吉西他滨耐药[J].武汉大学学报（医学版）,2025,46(07):850-856. DOI： 10.14188/j.1671-8852.2023.0508.

SUN Yunpeng,WU Huanhuan,ZHUANG Lei,et al.Exosomal delivery of lncRNA RPL23AP82 promotes gemcitabine resistance in pancreatic ductal adenocarcinoma[J].Medical Journal of Wuhan University,2025,46(07):850-856. DOI： 10.14188/j.1671-8852.2023.0508.

摘要

目的

探究外泌体传递lncRNA RPL23AP82促进胰腺导管腺癌（PDAC）吉西他滨（GEM）耐药。

方法

（1）构建lncRNA RPL23AP82过表达载体并转染至SW1990细胞中后用GEM进行干扰、分组，对比细胞增殖活性、细胞凋亡。（2）SW1990细胞系转染shRNA‑RPL23AP82并分组，对比miR‑129、PFTK1 mRNA与PFTK1蛋白表达；SW1990细胞系转染miR‑129 mimics或miR‑129 inhibitor，对比PFTK1 mRNA、PFTK1蛋白表达。（3）SW1990细胞系诱导构建GEM耐受型PDAC细胞（SW1990‑GR）并提取外泌体与亲本细胞孵育，分别根据加入GEM、转染sh‑NC或sh‑RPL23AP82、转染sh‑NC或外泌体抑制剂GW4869，对比lncRNA RPL23AP82表达、GEM敏感性变化、细胞凋亡、细胞增殖活性。

结果

（1）对比LV‑NC组，LV‑RPL23AP82组RPL23AP82相对表达量、细胞增殖活性更高且细胞凋亡更低，LV‑NC+GEM组细胞增殖活性更低，LV‑RPL23AP82+GEM组细胞增殖活性低于LV‑RPL23AP82组（均

0.05）。（2）sh‑RPL23AP82组中RPL23AP82相对表达量低于sh‑NC组，对比sh‑NC组，sh‑RPL23AP82组miR‑129表达升高且PFTK1 mRNA、PFTK1蛋白均下降（均

0.05）；对比NC mimics组，miR‑129 mimics组miR‑129表达升高且miR‑129 inhibitor组miR‑129表达降低，miR‑129 mimics组PFTK1 mRNA和PFTK1蛋白水平降低，而miR‑129 inhibitor组PFTK1 mRNA和PFTK1蛋白水平升高（均

0.05）。（3）SW1990‑GR组lncRNA RPL23AP82表达、SW1990‑GR组细胞增殖活性升高，对比SW1990‑GR组，SW1990‑GR+GEM组细胞增殖活性下调且细胞凋亡升高，耐药细胞SW1990‑GR与GEM共干扰后细胞凋亡下降（均

0.05）；敲低RPL23AP82后细胞增殖活性下调；GW4869抑制外泌体分泌后GW4869降低，抑制细胞增殖活性；抑制剂GW4869处理细胞增殖活性下降，细胞凋亡上升（均

0.05）。

结论

外泌体上调lncRNA RPL23AP82可降低miR‑129表达并通过刺激PFTK1表达促进吉西他滨耐药。

Abstract

Objective

To probe exosomal delivery of lncRNA RPL23AP82 to promote gemcitabine (GEM) resistance in pancreatic ductal adenocarcinoma (PDAC).

Methods

(1) The lncRNA RPL23AP82 overexpression vector was constructed and transfected into SW1990 cells

after which they were interfered with and grouped with GEM to compare their proliferative activity and apoptosis. (2) SW1990 cell lines were transfected with shRNA⁃RPL23AP82 and grouped to compare miR⁃129

PFTK1 mRNA with PFTK1 protein expression; SW1990 cell lines were transfected with miR⁃129 mimics or miR⁃129 inhibitor

comparing PFTK1 mRNA

PFTK1 protein expression. (3) SW1990 cell line was induced to construct GEM‑resistant PDAC cells (SW1990‑GR) and exosomes were extracted and incubated with the parental PDAC cells. According to the addition of GEM

transfection with sh‑NC or sh‑RPL23AP82

transfection with sh‑NC or exosome inhibitor GW4869

the patients were divided into groups. The lncRNA RPL23AP82 expression

GEM sensitivity

cell apoptosis and cell proliferation activity were compared.

Results

(1) Compared with the LV⁃NC group

the relative expression of RPL23AP82

cell proliferation activity

and apoptosis were higher and lower in the LV⁃RPL23AP82 group

cell proliferation activity was lower in the LV⁃NC+GEM group

and cell proliferation activity was higher in the LV⁃RPL23AP82+GEM group than in the LV⁃RPL23AP82 group (all

0.05). RPL23AP82+GEM group had lower cell proliferation activity than the LV⁃RPL23AP82 group (all

0.05). (2) The relative expression of RPL23AP82 in the sh⁃RPL23AP82 group was lower than that in the sh⁃NC group; comparing with the sh⁃NC group

miR⁃129 expression was elevated in the sh⁃RPL23AP82 group and PFTK1 mRNA and PFTK1 protein were decreased (both

0.05); compared with the NC mimics group

miR⁃129 expression was elevated in the miR⁃129 mimics group and decreased in the miR⁃129 inhibitor group

and miR⁃129 expression was increased in the sh⁃NC group

and miR⁃129 expression was decreased in the sh⁃NC group

and miR⁃129 expression was increased in the sh⁃NC group. The miR⁃129 expression was decreased in the miR⁃129 mimics group

and PFTK1 mRNA and PFTK1 protein levels were decreased in the miR⁃129 mimics group

while PFTK1 mRNA and PFTK1 protein levels were increased in the miR⁃129 inhibitor group (both

0.05). (3) The expression of lncRNA RPL23AP82 in the SW1990⁃GR group and cell proliferative activity was elevated in the SW1990⁃GR group

com

pared with the SW1990⁃GR group

cell proliferative activity was down⁃regulated in the SW1990⁃GR+GEM group and apoptosis was elevated

apoptosis decreased after co⁃disturbance of SW1990⁃GR and GEM in drug⁃resistant cells (both

0.05); cell proliferative activity was down⁃regulated after knockdown of RPL23AP82; GW4869 inhibition of exosome secretion decreased after GW4869 inhibition and inhibited cell proliferative activity; proliferative activity of inhibitor GW4869⁃treated cells decreased and apoptosis rose (both

0.05).

Conclusion

Exosomal upregulation of lncRNA RPL23AP82 reduces miR⁃129 expression and promotes gemcitabine resistance by stimulating PFTK1 expression.

关键词

Keywords

references

FERENCZ S , REGLODI D , KASZAS B , et al . PACAP and PAC1 receptor expression in pancreatic ductal carcinoma [J ] . Oncol Lett , 2019 , 18 ( 6 ): 5725 ‑ 5730 .

MULLER M , HAGHNEJAD V , SCHAEFER M , et al . The immune landscape of human pancreatic ductal carcinoma: Key players, clinical implications, and challenges [J ] . Cancers , 2022 , 14 ( 4 ): 995 .

SARVEPALLI D , RASHID M U , RAHMAN A U , et al . Gemcitabine: A review of chemoresistance in pancreatic cancer [J ] . Crit Rev Oncog , 2019 , 24 ( 2 ): 199 ‑ 212 .

JIANG X Y , MA Y , WANG T , et al . Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress [J ] . Gastroenterology , 2023 , 164 ( 7 ): 1232 ‑ 1247 .

陈升阳 , 陈艳军 , 胡水全 , 等 . lncRNA HOXA‑AS2在胰腺癌组织中的表达及对细胞增殖和侵袭力的影响 [J ] . 实用医学杂志 , 2021 , 37 ( 14 ): 1795 ‑ 1799 .

CHEN S Y , CHEN Y J , HU S Q , et al . Expression of lncRNA HOXA‑AS2 in pancreatic cancer tissues and its effect on cell proliferation and invasion [J ] . J Pract Med , 2021 , 37 ( 14 ): 1795 ‑ 1799 .

YANG J H , XU J , ZHANG B , et al . Ferroptosis: At the crossroad of gemcitabine resistance and tumorigenesis in pancreatic cancer [J ] . Int J Mol Sci , 2021 , 22 ( 20 ): 10944 .

PANDIT B , ROYZEN M . Recent development of prodrugs of gemcitabine [J ] . Genes , 2022 , 13 ( 3 ): 466 .

SUN Y P , ZHU Q D , YANG W J , et al . LncRNA H19/miR‑194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer [J ] . J Cell Biochem , 2019 , 120 ( 3 ): 3874 ‑ 3886 .

陈龙江 , 汤志刚 . 长链非编码RNA介导的分子调控机制在胰腺癌中的研究进展 [J ] . 中华实验外科杂志 , 2021 , 38 ( 10 ): 2085 ‑ 2089 .

CHEN L J , TANG Z G . Research progress of molecular mechanism mediated by long noncoding RNA in pancreatic cancer [J ] . Chin J Exp Surg , 2021 , 38 ( 10 ): 2085 ‑ 2089 .

郭晨博 , 毛玉宁 , 张延英 , 等 . 长链非编码RNA在胰腺癌吉西他滨耐药研究中的作用 [J ] . 中国比较医学杂志 , 2022 , 32 ( 7 ): 131 ‑ 136 .

GUO C B , MAO Y N , ZHANG Y Y , et al . Role of long noncoding RNAs in gemcitabine resistance of pancreatic cancer [J ] . Chin J Comp Med , 2022 , 32 ( 7 ): 131 ‑ 136 .

央茂 , 冯佳毅 , 刘颖斌 . 胰腺癌化疗中吉西他滨耐药机制研究进展 [J ] . 中国实用外科杂志 , 2022 , 42 ( 2 ): 225 ‑ 229 .

YANG M , FENG J Y , LIU Y B . Advances in the mechanism of gemcitabine resistance in pancreatic cancer chemotherapy [J ] . Chin J Pract Surg , 2022 , 42 ( 2 ): 225 ‑ 229 .

ZHOU C F , YI C H , YI Y X , et al . LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β‑catenin and autophagy pathway through modulating the miR‑619‑5p/Pygo2 and miR‑619‑5p/ATG14 axes [J ] . Mol Cancer , 2020 , 19 ( 1 ): 118 .

CARNIE L E , LAMARCA A , VAUGHAN K , et al . Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): A study protocol [J ] . BMJ Open , 2021 , 11 ( 5 ): e042067 .

王智刚 , 杨睿 , 彭敏劼 , 等 . 外泌体微小RNAs介导的胰腺癌耐药机制研究进展 [J ] . 中华消化外科杂志 , 2021 , 20 ( 4 ): 471 ‑ 478 .

WANG Z G , YANG R , PENG M J , et al . Research advances of exosome miRNA‑mediated drug‑resistance in pancreatic cancer [J ] . Chin J Dig Surg , 2021 , 20 ( 4 ): 471 ‑ 478 .

徐彪铭 , 左朝晖 . 外泌体作为药物载体在胰腺癌化学治疗中的作用 [J ] . 中南大学学报(医学版) , 2023 , 48 ( 2 ): 268 ‑ 274 .

XU B M , ZUO C H . Effect of exosomes as drug carriers in chemotherapy of pancreatic cancer [J ] . J Cent South Univ Med Sci , 2023 , 48 ( 2 ): 268 ‑ 274 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

LGR4 affects benign prostatic hyperplasia by regulating the expression of androgen receptor and estrogen receptor α

Effect of NGALR overexpression on proliferation and apoptosis of renal tubular epithelial cells and its possible mechanism

Role of subunit HbA1c in the development of lung cancer

Effect of miR⁃3605⁃5p on the invasion and proliferation of renal cell carcinoma A498 cells by regulating TRPV4 expression

Research progress on the current status of surveillance and the influencing factors for gastric precancerous conditions and precancerous lesions

Related Author

SUN Yunpeng

QIU Jizhang

ZHAO Yiqiao

ZHANG Xinhua

FANG Xun

CHEN Wenli

ZENG Xingruo

CHEN Longmin

Related Institution

Department of Urology, Zhongnan Hospital of Wuhan University

Institute of Urology, Wuhan University

Dept. of Rheumatology and Immunology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Dept. of Clinical Laboratory， The Third Affiliated Hospital of Kunming Medical University

Dept. of Urology， Zhongnan Hospital of Wuhan University

AI问答

⁰